In this episode, we speak to Claire Skentelbery, Director General, EuropaBio, about the biotech revolution, including how biotech companies could contribute to the European economy in the future and the readiness of Europe to deliver these innovative solutions at scale. The GOLD team also discusses the biotech revolution from an investor's perspective, exploring the risks and rewards of investing in therapies driven by biotechnology.

Click here to subscribe to the weekly newsletter for more insights from GOLD.

If you're interested in learning more about the topic areas discussed in this episode, check out the following content:

A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech

Nurturing homegrown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe

The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies

S02 E06: Risks, rewards and future potential of biotechnology